Citigroup
SMMT icon

Citigroup’s Summit Therapeutics SMMT Stock Holding History

Citigroup’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57,500
Closed -$1.11M – 5889
2025
Q1 		$1.11M Buy
+57,500
New +$1.15M ﹤0.01% 3178

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup's SMMT Position: Q1 2026 in Review

Citigroup increased its Summit Therapeutics (SMMT) stake by 53% in Q1 2026, buying an estimated $1.12M and bringing the position to 199,133 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2180.

Citigroup first reported a position in SMMT in Q2 2015 and has held it in 36 quarters since. The position peaked at $5.7M in Q1 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Citigroup held 199,133 shares of Summit Therapeutics worth $3.78M as of Q1 2026.
  • Citigroup bought 69,207 Summit Therapeutics shares in Q1 2026, an estimated $1.12M.
  • Summit Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2180 holding.
  • Citigroup first reported a position in Summit Therapeutics in Q2 2015 and has held it in 36 quarters since.
  • Citigroup's Summit Therapeutics position peaked at $5.7M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.